An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide

Cancer immunity

Ghulam Mufti⁵  Ghazala Khan³  Barbara-ann Guinn⁴  Freda Stevenson²  Sarah Buchan²  Nicola Hardwick⁵  Karen Pulford¹  Jason Rice²  Wendy Ingram⁵  Gisella Vittes² 

[1] Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United KingdomNuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United KingdomNuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;Genetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United Kingdom;Department of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United Kingdom;Department of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomGenetic Vaccine Group, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Southampton, United KingdomDepartment of Life Sciences, University of Bedfordshire, Park Square, Luton, United Kingdom;Department of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United KingdomDepartment of Haematological Medicine, King’s College London School of Medicine, The Rayne Institute, London, United Kingdom

关键词: PASD1;    immunotherapy;    acute myeloid leukemia;    DNA vaccine;    analogue peptide;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown